Cue Biopharma, Inc. Common Stock (CUE) Stock
NASDAQ · CUE
37.05
Fundamentals
Market cap
$269.15M
Price / Earnings ratio
-1.7x
Price / Sales ratio
7.3x
Price / Book ratio
119.0x
Return on assets
-0.5%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Cue Biopharma, Inc. Common Stock
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
SectorHealthcare
IndustryBiotechnology
Employees29
CEODr. Shao-Lee Lin M.D., Ph.D.
IPO DateJan 2, 2018
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Lucinda Warren | Principal Accounting Officer & Chief Business Officer | 1969 |
| Mr. Colin G. Sandercock J.D., MSE | Senior Vice President of Intellectual Property | 1957 |
| Dr. Shao-Lee Lin M.D., Ph.D. | President, CEO & Director | 1967 |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder | 1976 |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder | 1973 |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific & Clinical Advisory Board | 1961 |
| Mr. James M. Ahlers | Chief Financial Officer | 1964 |
| Ms. Agnes Lee | Chief Officer of Public & Investor Relations | — |
| Ms. Sumita Ray J.D. | Chief Legal & Compliance Officer and Corporate Secretary | 1974 |
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer | 1950 |
Fundamentals
Valuation
Market cap$269.15M
Price-to-sales ratio7.30
Price-to-book value119.00
Price-earnings ratio-1.70
Return on Equity-98.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-26.42
Income Statement
Average volume162,352
EBITDA$-15.32M
1 year high (52w)$45.50
1 year low (52w)$0.17
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



